Chronic myeloid leukaemia (CML) blockbuster Gleevec has been badly hit by generic competition in the US, revenues falling 30% to $834 million in the period. This decline will continue, with ...
Through chemical changes, the binding affinity for ABL was improved compared with imatinib, making nilotinib ... blastic phase in both nilotinib arms (400 mg twice daily or 300 mg twice daily ...
France’s Minister of the Interior Bruno Retailleau during a visit focused on drug trafficking in Rennes, western France - Damien Meyer/AFP France has reached a “tipping point” on drug ...
France has reached a “tipping point” on drug-related violence, the country’s hardline interior minister warned on Friday, after hundreds of people took part in a massive shoot-out.
With the launch of Windsor EV, MG Motor India has emerged as one of the leading electric car manufacturers in the Asian subcontinent One of the most iconic car manufacturers in the world ...
Now, using DNA, 3D printing and modelling clay, a team of scientists has reconstructed Zosia's 400-year-old face, revealing the human story buried by supernatural beliefs. "It's really ironic ...
or a little over $400 per share. Now while such a decline in P/E multiple may appear drastic, Netflix stock typically reacts very sharply to news. The stock has seen drawdowns of over 70% in a ...
Using DNA, 3D printing and modelling clay, a team of scientists has reconstructed Zosia's 400-year-old face, revealing the human story buried by supernatural beliefs.
The first-line nod marks an important step for the Gleevec follow-up on its way toward reaching the company’s peak sales projection of $3 billion. Only about 15% of Ph+ CML patients reach the ...
After adding both BEV and HEVs to its line-up, MG Motor Philippines is poised to add its first PHEV too. Previewed at the Philippine International Motor Show, the MG HS PHEV will be coming to the ...
The accelerated approval is based on major molecular response rate (MMR) at week 48 from the ASC4FIRST Phase III trial that compared once daily Scemblix to all other investigator-selected (IS) ...